Document Type : Original Article

Authors

1 Assistant Professor of Neurology, Neurology research Centre, Kerman University of Medical Sciences, Kerman, Iran

2 Professor of Neurology, Neurology Research Centre, Kerman University of Medical Sciences, Kerman, Iran

3 Associate Professor of Ophthalmology, Ophthalmology Department, Kerman University of Medical Sciences, Kerman, Iran

4 Neurologist, Neurology Department, Kerman University of Medical Sciences, Kerman, Iran

5 Assistant Professor of Biostatistics and Epidemiology, School of Public Health, Kerman University of Medical Sciences, Kerman, Iran

Abstract

Introduction: We investigated correlation between the retinal nerve fiber layer (RNFL) thickness and the severity of Parkinson's disease (PD).
Methods: In this study, the RNFL thickness of 23 patients with Parkinson’s disease (PD) was compared to normal controls (NCs). PD severity was assessed by the MDS-UPDRS (movement disorder society Unified Parkinson Disease Rating Scale) rating scale thoroughly in all parts. RNFL is measured by Ocular Coherent tomography (OCT). Scatter plots were used to evaluate the relationship between disease severity and retinal thickness.
Results: The findings of the study demonstrated that patients with PD had a significantly thinner average RNFL thickness compared with controls (P=0.035). Superior and inferior retinal quadrants were thinnest in PD compared with the healthy group (P=0.021 and P=0.045, respectively). The MDS-UPDRS had a significant reverse correlation with RNFL (r = -0.518, P=0.011) and its temporal quadrant (r = -0.594, P=0.003). Among all parts of MDS-UPDRS scale, Part III had the strongest correlation with OCT findings.
Conclusion: A correlation was found between the severity of the disease and the thinning of RNFL. MDS-UPDRS Part III subscale had the strongest correlation with RNFL thickness. Temporal quadrant RNFL became thinner as Parkinson’s disease severity increased.

 
 

Keywords

  1.  Lee JY, Kim JM, Ahn J, Kim HJ, Jeon BS, Kim TW. Retinal nerve fiber layer thickness and visual hallucinations in parkinson's disease. Mov Disord 2014; 29(1):61-7.
  2. Nowacka B, Lubiński W, Karczewicz D. Ophthalmological and electrophysiological features of Parkinson's disease. Klin Oczna 2010; 112(7-9):247-52.
  3. Moschos MM, Tagaris G, Markopoulos I, Margetis I, Tsapakis S, Kanakis M, et al. Morphologic changes and functional retinal impairment in patients with Parkinson disease without visual loss. Eur J Ophthalmol 2011; 21(1):24-9.
  4. Bodis-Wollner I, Glazman S, Yerram S. Fovea and foveation in Parkinson's disease. Behav Neurosci 2013; 127(2):139-50.
  5. Lee JY, Ahn J, Kim TW, Jeon BS. Optical coherence tomography in parkinson's disease: is the retina a biomarker? J Parkinsons Dis 2014; 4(2):197-204.
  6. Adam CR, Shrier E, Ding Y, Glazman S, Bodis-Wollner I. Correlation of inner retinal thickness evaluated by spectral-domain optical coherence tomography and contrast sensitivity in Parkinson disease. J Neuroophthalmol 2013 33(2):137-42.
  7. Satue M, Garcia-Martin E, Fuertes I, Otin S, Alarcia R, Herrero R, et al. Use of fourier-domain OCT to detect retinal nerve fiber layer degeneration in parkinson's disease patients. Eye (Lond) 2013; 27(4):507-14.
  8. Bodis-Wollner I, Miri S, Glazman S. Venturing into the no-man's land of the retina in Parkinson's disease. Mov Disord 2014; 29(1):15-22.
  9. Inzelberg R, Ramirez JA, Nisipeanu P, Ophir A. Retinal nerve fiber layer thinning in parkinson disease. Vision Res 2004; 44(24):2793-7.
  10. Chrysou A, Jansonius NM, van Laar T. Retinal layers in parkinson's disease: a meta-analysis of spectral-domain optical coherence tomography studies. Parkinsonism Relat Disord 2019; 64:40-49.
  11. Eraslan M, Cerman E, Yildiz Balci S, Celiker H, Sahin O, Temel A, et al. The choroid and lamina cribrosa is affected in patients with parkinson's disease: enhanced depth imaging optical coherence tomography study. Acta Ophthalmol 2016; 94(1):e68-75.
  12. Kromer R, Buhmann C, Hidding U, Keserü M, Keserü D, Hassenstein A, et al. Evaluation of retinal vessel morphology in patients with parkinson's disease using optical coherence tomography. PLoS One 2016; 11(8):e0161136.
  13. Ferro Desideri L, Barra F, Ferrero S. Systemic and intraocular factors related to retinal thicknesses variations in patients with Parkinson's disease. Parkinsonism Relat Disord 2019; 61:234-5.
  14. Gulmez Sevim D, Unlu M, Sonmez S, Gultekin M, Karaca C, Ozturk Oner A. Retinal vessel diameter obtained by optical coherence tomography is spared in parkinson's disease. Int Ophthalmol 2019; 39(4):813-9.
  15. Schneider M, Müller HP, Lauda F, Tumani H, Ludolph AC, Kassubek J, et al. Retinal single-layer analysis in parkinsonian syndromes: an optical coherence tomography study. J Neural Transm (Vienna) 2014; 121(1):41-7.
  16. Gulmez Sevim D, Unlu M, Gultekin M, Karaca C, Mirza M, Mirza GE. Evaluation of retinal changes in progressive supranuclear palsy and parkinson disease. J Neuroophthalmol 2018; 38(2):151-5.
  17. Bernardin F, Schwan R, Lalanne L, Ligier F, Angioi-Duprez K, Schwitzer T, et al. The role of the retina in visual hallucinations: a review of the literature and implications for psychosis. Neuropsychologia 2017; 99:128-38.
  18. Yang ZJ, Wei J, Mao CJ, Zhang JR, Chen J, Ji XY, et al. Retinal nerve fiber layer thinning: a window into rapid eye movement sleep behavior disorders in Parkinson's disease. Sleep Breath 2016; 20(4):1285-92.
  19. Bayhan HA, Aslan Bayhan S, Tanık N, Gürdal C. The association of spectral-domain optical coherence tomography determined ganglion cell complex parameters and disease severity in Parkinson's disease. Curr Eye Res 2014; 39(11):1117-22.
  20. Jiménez B, Ascaso FJ, Cristóbal JA, López del Val J. Development of a prediction formula of Parkinson disease severity by optical coherence tomography. Mov Disord 2014; 29(1):68-74.
  21. Roth NM, Saidha S, Zimmermann H, Brandt AU, Isensee J, Benkhellouf-Rutkowska A, et al. Photoreceptor layer thinning in idiopathic Parkinson's disease. Mov Disord 2014; 29(9):1163-70.
  22. Sen A, Tugcu B, Coskun C, Ekinci C, Nacaroglu SA. Effects of levodopa on retina in parkinson disease. Eur J Ophthalmol 2014; 24(1):114-9.
  23. Li L, Ji X, Mao C, Chen Y, Guo S, Li S, et al. A clinical study of changes in retina and visual field in patients with early Parkinson's disease. Zhonghua Nei Ke Za Zhi 2015; 54(6):521-4. [In Chinese].
  24. Mailankody P, Battu R, Khanna A, Lenka A, Yadav R, Pal PK, et al. Optical coherence tomography as a tool to evaluate retinal changes in parkinson's disease. Parkinsonism Relat Disord 2015; 21(10):1164-9.
  25. Aydin TS, Umit D, Nur OM, Fatih U, Asena K, Nefise OY, et al. Optical coherence tomography findings in Parkinson's disease. Kaohsiung J Med Sci 2018; 34(3):166-71.
  26. Brandt AU, Zimmermann HG, Oberwahrenbrock T, Isensee J, Müller T, Paul F, et al. Self-perception and determinants of color vision in Parkinson's disease. J Neural Transm (Vienna) 2018; 125(2):145-52.
  27. Matlach J, Wagner M, Malzahn U, Schmidtmann I, Steigerwald F, Musacchio T, et al. Retinal changes in parkinson's disease and glaucoma. Parkinsonism Relat Disord 2018; 56:41-6.
  28. Yıldız D, Pekel NB, Yener NP, Seferoğlu M, Günes A, Sığırlı D. Assessment of neurodegeneration by optical coherence tomography and mini-mental test in parkinson's disease. Ann Indian Acad Neurol 2019; 22(2):212-6.
  29. Stemplewitz B, Keserü M, Bittersohl D, Buhmann C, Skevas C, Richard G, et al. Scanning laser polarimetry and spectral domain optical coherence tomography for the detection of retinal changes in parkinson's disease. Acta Ophthalmol 2015; 93(8):e672-7.
  30. Pilat A, McLean RJ, Proudlock FA, Maconachie GD, Sheth V, Rajabally YA, et al. In vivo morphology of the optic nerve and retina in patients with parkinson's disease. Invest Ophthalmol Vis Sci 2016; 57(10):4420-7.
  31. Sengupta P, Dutta K, Ghosh S, Mukherjee A, Pal S, Basu D, et al. Optical coherence tomography findings in patients of parkinson's disease: an indian perspective. Ann Indian Acad Neurol 2018; 21(2):150-5.
  32. Litvinenko IV, Dynin PS, Trufanov AG, Gimadutdinov RF, Maltsev DS. Eye as an object of investigation of cognitive impairment in Parkinson's disease. Zh Nevrol Psikhiatr Im S S Korsakova 2018; 118(6. Vyp. 2):105-14. [In Russian].
  33. Garcia-Martin E, Rodriguez-Mena D, Satue M, Almarcegui C, Dolz I, Alarcia R, et al. Electrophysiology and optical coherence tomography to evaluate parkinson disease severity. Invest Ophthalmol Vis Sci 2014; 55(2):696-705.
  34. Eraslan M, Balci SY, Cerman E, Temel A, Suer D, Elmaci NT. Comparison of optical coherence tomography findings in patients with primary open-angle glaucoma and parkinson disease. J Glaucoma 2016; 25(7):e639-46.
  35. Cubo E, López Peña MJ, Diez-Feijo Varela E, Pérez Gil O, Garcia Gutierrez P, Araus González E, et al. Lack of association of morphologic and functional retinal changes with motor and non-motor symptoms severity in Parkinson's disease. J Neural Transm (Vienna) 2014; 121(2):139-45.
  36. Satue M, Seral M, Otin S, Alarcia R, Herrero R, Bambo MP, et al. Retinal thinning and correlation with functional disability in patients with Parkinson's disease. Br J Ophthalmol 2014; 98(3):350-5.
  37. Yu JG, Feng YF, Xiang Y, Huang JH, Savini G, Parisi V, et al. Retinal nerve fiber layer thickness changes in parkinson disease: a meta-analysis. PLoS One 2014; 9(1):e85718.
  38. Sari ES, Koc R, Yazici A, Sahin G, Ermis SS. Ganglion cell-inner plexiform layer thickness in patients with Parkinson disease and association with disease severity and duration. J Neuroophthalmol 2015; 35(2):117-21.
  39. Slotnick S, Ding Y, Glazman S, Durbin M, Miri S, Selesnick I, et al. A novel retinal biomarker for Parkinson's disease: quantifying the foveal pit with optical coherence tomography. Mov Disord 2015; 30(12):1692-5.
  40. Satue M, Obis J, Rodrigo MJ, Otin S, Fuertes MI, Vilades E, et al. Optical coherence tomography as a biomarker for diagnosis, progression, and prognosis of neurodegenerative diseases. J Ophthalmol 2016; 2016: 8503859.
  41. Ucak T, Alagoz A, Cakir B, Celik E, Bozkurt E, Alagoz G, et al. Analysis of the retinal nerve fiber and ganglion cell - Inner plexiform layer by optical coherence tomography in Parkinson's patients. Parkinsonism Relat Disord 2016; 31:59-64.
  42. Satue M, Rodrigo MJ, Obis J, Vilades E, Gracia H, Otin S, et al. Evaluation of progressive visual dysfunction and retinal degeneration in patients with parkinson's disease. Invest Ophthalmol Vis Sci 2017; 58(2):1151-7.
  43. Polo V, Satue M, Rodrigo MJ, Otin S, Alarcia R, Bambo MP, et al. Visual dysfunction and its correlation with retinal changes in patients with Parkinson's disease: an observational cross-sectional study. BMJ Open 2016; 6(5):e009658.
  44. Pillai JA, Bermel R, Bonner-Jackson A, Rae-Grant A, Fernandez H, Bena J, et al. Retinal nerve fiber layer thinning in alzheimer's disease: a case-control study in comparison to normal aging, parkinson's disease, and non-alzheimer's dementia. Am J Alzheimers Dis Other Demen 2016; 31(5):430-6.
  45. Archibald NK, Clarke MP, Mosimann UP, Burn DJ. Retinal thickness in parkinson's disease. Parkinsonism Relat Disord 2011; 17(6):431-6.
  46. Tian T, Zhu XH, Liu YH. Potential role of retina as a biomarker for progression of parkinson's disease. Int J Ophthalmol 2011; 4(4):433-8.
  47. Bodis-Wollner I. Foveal vision is impaired in Parkinson's disease. Parkinsonism Relat Disord 2013; 19(1):1-14.
  48. Kirbas S, Turkyilmaz K, Tufekci A, Durmus M. Retinal nerve fiber layer thickness in parkinson disease. J Neuroophthalmol 2013; 33(1):62-5.